It is crucial to consider that most analyses assessed by clinical trials and observational studies belong to an era when the potential for immunotherapy has not been yet available for patients with recurrent metastatic tumors, especially those with BRAF-mutated MSI. This evidence concerns the gene BRAF and metastatic neoplasm.